Imperial College London
Alternate

ProfessorMarie-ClaudeBoily

Faculty of Medicine, School of Public Health

Professor of Mathematical Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 3263mc.boily

 
 
//

Location

 

LG26Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Gottlieb:2019:10.1016/j.vaccine.2017.10.084,
author = {Gottlieb, SL and Giersing, BK and Hickling, J and Jones, R and Deal, C and Kaslow, DC and Boily, M-C and Brady, M and Broutet, N and Chirenje, ZM and Delany-Moretlwe, S and Johnston, C and Koelle, DM and Leone, P and Looker, K and Low, N and Madhivanan, P and Mugo, N and Nagot, N and Schillinger, J and Southem, J and Toledo, JP and Wald, A and Zhou, P},
doi = {10.1016/j.vaccine.2017.10.084},
journal = {Vaccine},
pages = {7408--7418},
title = {Meeting report: initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017},
url = {http://dx.doi.org/10.1016/j.vaccine.2017.10.084},
volume = {37},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The development of vaccines against herpes simplex virus (HSV) is an important global goal for sexual and reproductive health. A key priority to advance development of HSV vaccines is the definition of preferred product characteristics (PPCs), which provide strategic guidance on World Health Organization (WHO) preferences for new vaccines, specifically from a low- and middle-income country (LMIC) perspective. To start the PPC process for HSV vaccines, the WHO convened a global stakeholder consultation in March 2017, to define the priority public health needs that should be addressed by HSV vaccines and discuss the key considerations for HSV vaccine PPCs, particularly for LMICs. Meeting participants outlined an initial set of overarching public health goals for HSV vaccines in LMICs, which are: to reduce the acquisition of HIV associated with HSV-2 infection in high HIV-prevalence populations and to reduce the burden of HSV-associated disease, including mortality and morbidity due to neonatal herpes and impacts on sexual and reproductive health. Participants also considered the role of prophylactic versus therapeutic vaccines, whether both HSV-2 and HSV-1 should be targeted, important target populations, and infection and disease endpoints for clinical trials. This article summarizes the main discussions from the consultation.
AU  - Gottlieb,SL
AU  - Giersing,BK
AU  - Hickling,J
AU  - Jones,R
AU  - Deal,C
AU  - Kaslow,DC
AU  - Boily,M-C
AU  - Brady,M
AU  - Broutet,N
AU  - Chirenje,ZM
AU  - Delany-Moretlwe,S
AU  - Johnston,C
AU  - Koelle,DM
AU  - Leone,P
AU  - Looker,K
AU  - Low,N
AU  - Madhivanan,P
AU  - Mugo,N
AU  - Nagot,N
AU  - Schillinger,J
AU  - Southem,J
AU  - Toledo,JP
AU  - Wald,A
AU  - Zhou,P
DO  - 10.1016/j.vaccine.2017.10.084
EP  - 7418
PY  - 2019///
SN  - 0264-410X
SP  - 7408
TI  - Meeting report: initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017
T2  - Vaccine
UR  - http://dx.doi.org/10.1016/j.vaccine.2017.10.084
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000501402100016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S0264410X17314925?via%3Dihub
UR  - http://hdl.handle.net/10044/1/75868
VL  - 37
ER  -
Download